FDA approves new treatment for ALS
More information about Radicava (Edaravone) and when it will be available in the US.
Trial News & Events
FDA Approves Edaravone to Treat ALS
Today, the FDA approved the drug Edaravone for the treatment of ALS. NEALS is thrilled to now have another medication for our patients. For more information on how to access Edaravone, contact the staff and physicians at your ALS Clinic.
Call for Nominations: 2017 Clinical Research Learning Institute
Nominations and self-nominations are now being accepted for the 2017 Clinical Research Learning Institute (CRLI)! Patients, caregivers and patient-caregiver pairs are encouraged to apply.
ALS: New Research & Studies
NEALS Research Ambassadors, Stephen Winthrop and Pete Frates, were recently interviewed by WCVB, the Boston ABC affiliate, about their commitment to clinical trials and the fight against ALS.
ALS Research Ambassador on the Importance of Multidisciplinary Care
Madeline Kennedy describes the benefits of a multidisciplinary care approach for people living with ALS.
PALS Webinar - Cannabinoid use in ALS: Only symptom management or more?
Please join us on March 23rd for a webinar discussion on cannabinoid use in ALS led by Drs. Mark Ware and Angela Genge from the Montreal Neurological Institute and Hospital. Dr. Ware will discuss the mechanism of action of cannabinoids, while Dr. Genge will discuss their use in symptom management, and possible effect on disease course.
ALS At Home
Barrow Neurological Institute is seeking individuals to participate in a remote research study called ALS AT HOME, enrolling under the direction of Dr. Jeremy Shefner.
NEALS Principal Investigator Training Seminar
NEALS is pleased to announce a full day training session for NEALS investigators interested in developing and conducting multi-center ALS clinical trials as Principal Investigators.
Neuraltus Pharmaceuticals is Now Enrolling in Phase 2 Trial of NP001
Neuraltus Pharmaceuticals, Inc., is currently enrolling up to 120 individuals with ALS and evidence of systemic inflammation in a second Phase 2 study of its investigational treatment NP001, an immune system regulator.
Watch Presentations from the 6th Annual Les Turner Symposium on ALS
At the 6th Annual Les Turner Symposium on ALS and NeuroRepair, sponsored by the Les Turner ALS Research and Patient Center at Northwestern Medicine held in November 2016, a crowd of over 175 attendees learned the latest in ALS research and patient care from experts in the field.